<DOC>
	<DOCNO>NCT02246764</DOCNO>
	<brief_summary>The purpose study evaluate ocular systemic safety Netarsudil ( AR-13324 ) Ophthalmic Solution , 0.02 % q.d . b.i.d . 12 month compare active comparator Timolol Maleate Ophthalmic Solution , 0.5 % .</brief_summary>
	<brief_title>Study Netarsudil ( AR-13324 ) Ophthalmic Solution Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . 19 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . 3 . Unmedicated ( postwashout ) IOP &gt; 20 mm Hg &lt; 27 mm Hg study eye 2 qualification visit ( 08:00 hr ) , 27 day apart . At second qualification visit , IOP &gt; 17 mm Hg &lt; 27 mm Hg 10:00 16:00 hr ( eye ) . 4 . Corrected visual acuity eye +1.0 logMAR good ETDRS eye ( equivalent 20/200 ) . 5 . Able willing give sign informed consent follow study instruction . Ophthalmic : 1 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure , narrow angle . Note : Previous laser peripheral iridotomy NOT acceptable . 2 . Intraocular pressure ≥27 mm Hg ( unmedicated ) eye ( individual exclude criterion allow attempt requalification ) , use two ocular hypotensive medication within 30 day screen . Note : fix dose combination count two medication . 3 . Known hypersensitivity component formulation use ( benzalkonium chloride , etc . ) , topical anesthetic βadrenoceptor antagonist . 4 . Previous glaucoma intraocular surgery glaucoma laser procedures either eye . 5 . Refractive surgery either eye ( e.g. , radial keratotomy , PRK , LASIK , corneal crosslinking , etc. ) . 6 . Ocular trauma either eye within six month prior screen , ocular surgery nonrefractive laser treatment within three month prior screen . 7 . Recent current evidence ocular infection inflammation either eye . Current evidence clinically significant blepharitis , conjunctivitis , history herpes simplex zoster keratitis screen either eye . 8 . Ocular medication either eye kind within 30 day screen , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , screen ) c ) lubricate drop dry eye ( may use throughout study ) . 9 . Clinically significant ocular disease either eye ( e.g. , corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( e.g. , cupdisc ratio &gt; 0.8 , severe visual field defect ) . 10 . Central corneal thickness either eye great 600 µm screening . 11 . Any abnormality either eye prevent reliable applanation tonometry either eye . Systemic : 12 . Clinically relevant abnormality ( determined investigator ) laboratory test screen may impact study . 13 . Known hypersensitivity contraindication betaadrenoceptor antagonist ( e.g. , chronic obstructive pulmonary disease bronchial asthma ; abnormally low blood pressure heart rate ; second third degree heart block congestive heart failure ; severe diabetes ) . 14 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , endocrine cardiovascular disorder ) might interfere study . 15 . Participation investigational study within 30 day prior screen . 16 . Changes systemic medication could effect IOP within 30 day prior screen , anticipate study . 17 . Women childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ocular hypertension .</keyword>
	<keyword>Glaucoma</keyword>
</DOC>